Aldeyra治疗药物的库存猛跌75%, 因为林业发展局要求对其干眼药进行更多的试验, Aldeyra Therapeutics' stock plunges 75% as FDA demands more trials for its dry eye drug, reproxalap.

Aldeyra治疗药物的库存在林业发展局就其干眼病药物发布全面反应函后下降了75%。 Aldeyra Therapeutics' stock fell by 75% after the FDA issued a Complete Response Letter for its dry eye disease drug, reproxalap, citing concerns over trial data. 美国食品药品管理局要求进行更多的研究来证明药物的有效性. The FDA requires additional studies to demonstrate the drug's efficacy. 生物技术公司目前正在因可能违反证券法而被调查。 The biotech company is now under investigation for potential securities law violations. Aldeyra计划在第二季度发布更多的试验数据,并在今年晚些时候重新提交药物申请。 Aldeyra plans to release more trial data in the second quarter and resubmit the drug application later this year.